Keywords: Astex, GlaxoSmithKline, Research, Licensing, Cancer
Astex could earn $500 million from strategic drug discovery alliance with GlaxoSmithKline
Article | 13 November 2009
Cambridge, UK-based cancer therapy developer Astex Therapeutics has entered into a new collaboration deal with GlaxoSmithKline to discover, develop and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
